Purpose: To investigate the value of using changes in 3 parameters (tumor size, transfer constant (K trans ), and rate constant (k ep )) obtained after the first treatment-cycle in predicting the final clinical response after 2 to 4 cycles of neoadjuvant AC-chemotherapy.
INTRODUCTION
Neoadjuvant or preoperative chemotherapy is increasingly becoming an important part of breast cancer treatment and management. Especially in patients with locally advanced cancers, neoadjuvant chemotherapy has become the standard to allow downstaging of cancers to render them operable and/or to facilitate breast conservation surgeries (1) (2) (3) (4) (5) . Neoadjuvant chemotherapy has also been shown to improve both relapse-free and overall survival in patients with inoperable locally advanced breast cancer (1, 2, (6) (7) (8) (9) . Patient undergoing neoadjuvant chemotherapy regimen also presents a unique opportunity to observe the change in tumor during treatment to assess treatment efficacy. It also provides an opportunity to intervene during treatment based on response, so that the patient could be spared of the associated morbidity by early termination of an ineffective regimen and benefit from effective regimens sooner.
The most commonly used means for evaluating the chemotherapeutic response in breast cancer is still clinical examination based on a palpable change in tumor size, which is highly subjective and can be inaccurate. Conventional imaging techniques such as mammography and ultrasound can be used to evaluate response; however, partly due to therapy induced fibrosis they may not be very accurate (6, 7, (10) (11) (12) (13) (14) . Due to its superior spatial resolution, 3-dimensional coverage, and high sensitivity, contrast enhanced MRI is emerging as the best imaging technique for investigating response of breast cancer to neoadjuvant chemotherapy (15) (16) (17) (18) . Gilles et al (19) first demonstrated the ability of contrast-enhanced MRI in depicting residual breast tumor after neoadjuvant chemotherapy and showed a good agreement (83%) between MRI and pathologic assessment. A similar finding in MRI evaluation of residual tumor size was reported 4 subsequently by other research groups (20) (21) (22) (23) (24) (25) (26) . Extensive comparison of contrastenhanced MRI in evaluation of tumor response to other conventional techniques including physical examination, mammography and ultrasound was reported by Weatherall et al (27) and Balu-Maestro et al (22) . Both studies reported more reliable evaluation of residual tumor size by MRI in comparison to histopathological findings than by other techniques.
Analysis of the signal enhancement time-course obtained from DCE-MRI in neoadjuvant chemotherapy response study has been investigated. Qualitative analytic approach without using modeling analysis was reported by Rieber et al (25) and Martincich et al (26) . Rieber et al reported a decreased intensity of contrast medium uptake in 88.2% of breast cancer patients with partial response and all patients with complete response. Martinicich et al reported that combining tumor volume and early enhancement ratio after two cycles of primary chemotherapy yielded a 93% diagnostic accuracy in identifying breast tumors achieving a pathological complete response. Hayes et al (28) investigated correlations between qualitative and quantitative analytic methods using Tofts model (29, 30) , and reported a reduction in K trans after 1 cycle of treatment more frequently in the eventual responders than in non-responders, which was strongly correlated to changes in the rate of enhancement. Recently several groups investigated the potential of using quantitative early size change and reduction in pharmacokinetic parameters, such as K trans and k ep , as a final response predictor in patients undergoing neoadjuvant chemotherapy (31) (32) (33) (34) . Different analysis techniques were applied, and different treatment protocols were used, but the general conclusion was that early 5 changes of tumor size was the best predictor, but the changes of pharmacokinetic parameters could also differentiate between responders and non-responders.
These published studies used various treatment regimens, with regular schedule, one cycle every 3 weeks. In this work we studied whether early changes in tumor size and pharmacokinetic parameters (K trans and k ep ) can predict outcome in patients receiving a dose-dense anthracycline-based neoadjuvant chemotherapy. Doxorubicin and Cyclophosphamide was given every 2 weeks instead of 3 weeks. Two MRI studies were performed for each patient, one pre-treatment (or baseline) MRI, and an early follow-up (F/U) MRI after 1 cycle of AC. For those patients who received 4 cycles of AC, another F/U MRI was performed at that time. According to their response patterns, patients were separated into 4 response groups, and also combined as overall responders and nonresponders. Based on comparisons between different response groups, we set out to answer 2 questions: 1) whether the early changes observed in tumor size and/or in pharmacokinetic parameters were different between these groups with different response pattern? 2) Can the measured changes in tumor size and/or pharmacokinetic parameters after 1 AC predict the final outcome after completing 4 cycles of AC?
MATERIALS AND METHODS

Patients
The study was a retrospective analysis of a prospective enrollment study. All eligible subjects enrolled into this study had core-biopsy proven primary breast cancer, normalized by the mean pre-contrast signal intensity. The enhancement kinetics was then analyzed based on the 2-compartmental pharmacokinetic model described by Tofts et al (29, 30 ) to obtain transfer constant and rate constant, K trans and k ep , (representing the uptake rate and wash-out rate, respectively). In our analysis the percent-enhancements were directly fitted without using assumptions to convert them to [Gd] concentration in the tissue; also the true blood [Gd] concentration was not assumed and only decay rate constants were used (34, 37) . Therefore, the obtained K trans still carried the % enhancement, in unit of (%/min), and k ep is a rate constant in unit of (1/min), exactly the same as the k ep in Tofts model (29, 30) . In order to improve the fitting quality, one additional independent parameter, t 0 , was allowed to adjust, where t 0 is the time interval over which the concentration of contrast medium is assumed to follow a linear increase phase in the plasma after injection (37) . The fitting process was carried out with software developed in-house using Matlab environment (version 6.0.0.88, The MathWorks, Inc.).
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Change in pharmacokinetic parameters observed in the F/U-1 MRI was measured as percentage change with respect to that of baseline MRI.
Statistical Analysis
The changes in tumor size and pharmacokinetic parameters after 1 cycle AC in each group were tested for statistical significance using a paired, two-tailed t-test. The mean baseline (pre-treatment) values of 3 parameters (tumor size, K trans , and k ep ) were compared among the 4 response groups using analysis of variance. Analysis of variance was also used to compare their percent changes after 1 cycle AC among the 4 response groups. Analysis using two-tailed t-test with unequal variance was performed to compare the percent changes between the overall responder and non-responder groups. The association between the early changes in pharmacokinetic parameters and tumor size observed in the F/U-1 study after 1 cycle AC was investigated using Pearson's regression analysis. The significance level in all statistical tests was set at P < 0.05. Receiver operating characteristic (ROC) analysis based on changes of 3 parameters after 1 AC to separate responders from non-responders was performed.
RESULTS
Four Therapy Response Groups and Their Baseline Parameters
Based on response criteria using the 2-D tumor size change after 1 and 4 cycles of AC as 28% and 50%, patients were separated into 4 response groups. There were 9 patients in Group-1 (R-R), 8 patients in Group-2 (NR-R), 3 patients in Group-3 (NR-11 NR), and 9 patients in Group-4 (NR-T). Consequently, there were 17 responders (combining Groups 1+2) and 12 non-responders (combining Groups 3+4). None of the baseline tumor size or pharmacokinetic parameters (Table 1) was statistically different among the 4 response groups or between the responders and non-responders.
Early Changes After 1 cycle AC
The observed changes in the 2-D tumor size, K trans , and k ep after 1 cycle AC were compared among the 4 response groups (Table 2 ). Only Group-1 (N = 9) showed significant reduction in tumor size and rate constant, k ep . None of the parameters in the other 3 groups showed significant changes. Within the overall responder and nonresponder groups, both tumor size and k ep showed significant reduction in responders, and none of the changes were significant in the non-responders. The early changes in 2-D tumor size, K trans , and k ep of all individual patients in each of 4 groups were plotted and compared in Figure 2 . A large variation was observed in all groups. Since the group separation was based on 28% tumor area reduction, Group-1 was clearly separated from Groups 2-4 in size change (Fig. 2a) . No other pairs among the 3 remaining groups showed differences in the change of tumor size. The changes observed in both K trans and k ep were significantly different between Group-1 and Group-4 ( Table 2 , P < 0.001 for K trans and P < 0.01 for k ep ). The most interesting comparison was between Group-2 patients (NR-R, N = 8) and Group-3 patients (NR-NR, N = 3), since they were nonresponders after 1 AC, but turned out to be final responders (Group-2) and nonresponders (Group-3) after 4 AC. However, none of the parameters showed significant 12 difference between them, i.e. no parameter after 1 AC could be used to predict their final response after 4 AC.
Analysis of Enhancement Kinetic Time Course
The percent signal enhancement time courses from 3 patients, one in each of the Groups 1-3 are shown ( Figure 3) . These are the same three patients whose MIPs were previously shown (Figure 1 ). Tumor with a higher vascular volume and vascular permeability will present a faster wash-in and a faster wash-out, leading to a higher K trans and a higher k ep value. In Fig. 3a , from the R-R patient in Fig. 1a , the fitted parameters 
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Association between Early Changes in Tumor Size and Pharmacokinetic
Parameters
Association between the measured changes in size and pharmacokinetic parameters after 1 cycle AC was investigated by pooling all patients together and using regression analysis ( Figure 4 ). The changes in both K trans and k ep were significantly correlated with tumor size changes: r = 0.49, P < 0.01 for K trans (Fig. 4a) and r = 0.66, P < 0.001 for k ep (Fig. 4b) . The results might suggest that changes in tumor size and pharmacokinetic parameters were both associated with therapy treatment. Between the two pharmacokinetic parameters, rate constant (k ep ) appeared to be more sensitive to treatment effects than transfer constant (K trans ). The changes in k ep were more strongly associated with the changes in tumor size with a higher linear correlation coefficient. The changes in k ep were also significantly different between the Responder and the Nonresponder groups, whereas the changes in K trans were not (Table 2 ).
Predictive Value of Early Changes in Tumor Size and Pharmacokinetic
Parameters
ROC analysis was performed based on the early changes observed in tumor size, K trans , and k ep to differentiate between overall responders and non-responder groups, i.e.
to predict the final outcome. ROC curves generated by all 3 parameters are plotted It is believed that a reduction in pharmacokinetic parameters in response to chemotherapy, such as amplitude, K trans and k ep , observed here and elsewhere, is associated with antivascular/antiangiogenesis effect of therapeutic agents to some extent, and as such, they may provide a different perspective other than cell death measured by tumor shrinkage. However, since all reported chemotherapy regimen mainly contain cytotoxic agents, such as anthracyclines (e.g., doxorubicin, epirubicin), taxanes (e.g., paclitaxel, docetaxel), and cyclophosphamide, the early change in tumor size still plays a major role in predicting response (23, 24, 26, (32) (33) (34) . Targeted, non-cytotoxic agents, 17 particularly anti-angiogenic drugs, however, are not anticipated to produce immediate tumor shrinkage, and pharmacokinetic parameters based on DCE-MRI may more likely play a significant role.
The reported results from different investigators could not be directly compared.
There was a great effort trying to bring all different models to converge to a unified one (29, 30) . In order to apply Tofts' model to obtain K trans in ( show response is influenced by treatment regimens and individual patients, and may vary from days to weeks. In our series we found some patients showed substantial tumor shrinkage 1 week after the first cycle was given (Group-1), and some did not (Group-2), however, they were eventual responders after 4 cycles of treatment. The analysis of DCE-MRI may further contribute to varying findings.
In this study the first F/U MRI for all patients were performed at a mean of 13 days after the first cycle of AC (± 4.6 [SD], median 13 days). Some patients might be followed too early before changes could occur. The F/U time was comparable between overall responder group (13 ± 5.3 [SD], median 13) and non-responder group (14 ± 3.6
[SD], median 14). The most interesting aspect in this study is to differentiate between Group-2 (NR-R) and Group-3 (NR-NR). They were non-responders in the F/U-1 study, but 8 turned out to be responders and 3 remained as non-responders. We compared the follow-up time between Group-2 (11 ± 3. Partly due to the small subject number in this group, it was difficult to find changes significantly different between Group-2 and Group-3.
In summary, to address the 2 questions: 1) whether the early changes observed in tumor size and/or in pharmacokinetic parameters were different between these groups with different response pattern? We found that changes in tumor size and k ep were significantly different between the overall responders (Groups 1+2) and non-responders could differentiate between them, thus not have a predictive value, within the limited number of subjects investigated in this study.
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